Table 4.
Substrate recurrence rate by substrate-specific parameters
| 0 to 2 Months | 2 to 6 Months+ | 6 to 12 Months+ | 0 to 6 Months | 0 to 12 Months | |
|---|---|---|---|---|---|
| Total substrates | 7.0% (35/500) | 2.3% (10/427) | 1.7% (6/352) | 9.2% | 10.7% |
| Substrate/pathway location | |||||
| Manifest accessory pathway | 9.7% (21/216) | 1.1% (2/183) | 0.7% (1/149) | 10.7% | 11.3% |
| Concealed accessory pathway | 6.6% (9/137) | 5.2% (6/116) | 4.2% (4/96) | 11.4% | 15.1% |
| PJRT | 20.0% (2/10) | 0.0% (0/6) | 0.0% (0/5) | 20.0% | 20.0% |
| AVNRT | 2.2% (3/134) | 1.7% (2/120) | 1.0% (1/100) | 3.9% | 4.8%*a |
| Atrial fibrillation | NA (0/0) | NA (0/0) | NA (0/0) | NA | NA |
| Atrial flutter/intraatrial reentry | 0.0% (0/1) | 0.0% (0/1) | 0.0% (0/1) | 0.0% | 0.0% |
| Ectopic atrial tachycardia | 0.0% (0/1) | NA (0/0) | NA (0/0) | NA | 0.0% |
| Junctional ectopic tachycardia | NA (0/0) | NA (0/0) | NA (0/0) | NA | NA |
| Ventricular tachycardia | NA (0/0) | NA (0/0) | NA (0/0) | NA | NA |
| Other (Mahaim) | 0.0% (0/1) | 0.0% (0/1) | 0.0% (0/1) | 0.0% | 0.0% |
| Power mode vs temperature mode | |||||
| Temperature control only | 7.0% (29/413) | 2.3% (8/354) | 1.0% (3/290) | 9.1% | 10.1% |
| Power control only | 20.0% (4/20) | 7.1% (1/14) | 0.0% (0/12) | 25.7% | 25.7%*b |
| Both temperature and power control | 0.0% (0/1) | 0.0% (0/1) | 0.0% (0/1) | 0.0% | 0.0% |
| Missing | 3.0% (2/66) | 1.7% (1/58) | 6.1% (3/49) | 4.7% | 10.5% |
| Duration of observation after last RF application (min) | |||||
| 0–30 | 8.0% (16/199) | 1.7% (3/173) | 2.1% (3/146) | 9.6% | 11.5% |
| 31–60 | 5.7% (12/209) | 3.3% (6/180) | 2.0% (3/149) | 8.9% | 10.7% |
| 61–90 | 5.4% (2/37) | 0.0% (0/30) | 0.0% (0/23) | 5.4% | 5.4% |
| >90 | 3.2% (1/31) | 0.0% (0/26) | 0.0% (0/22) | 3.2% | 3.2% |
| Missing | 16.7% (4/24) | 5.6% (1/18) | 0.0% (0/12) | 21.3% | 21.3% |
| Use of isoproterenol in postablation testing | |||||
| AVNRT w/isoproterenol | 1.8% (2/110) | 2.0% (2/99) | 1.2% (1/83) | 3.8% | 5.0% |
| AVNRT w/o isoproterenol | 4.2% (1/24) | 0.0% (0/21) | 0.0% (0/17) | 4.2% | 4.2% |
| Non-AVNRT w/isoproterenol | 8.3% (21/252) | 2.8% (6/218) | 2.2% (4/184) | 10.9% | 12.8% |
| Non-AVNRT w/o isoproterenol | 9.6% (11/114) | 2.2% (2/89) | 1.5% (1/68) | 11.7% | 13.0% |
| Pathway | |||||
| Right free wall | 15.8% (9/57) | 0.0% (0/46) | 0.0% (0/39) | 15.8% | 15.8% |
| Right septal | 14.1% (10/71) | 5.3% (3/57) | 7.3% (3/41) | 18.6% | 24.6%***c |
| Left septal | 4.8% (1/21) | 0.0% (0/18) | 0.0% (0/14) | 4.8% | 4.8% |
| Left free wall | 5.6% (12/215) | 2.7% (5/185) | 1.3% (2/157) | 8.1% | 9.3%**c |
+
Substrates with recurrences at end of interval/substrates known not to have prior recurrence at beginning of interval.
Statistical significance at
*
P < .05
**
P < .01
***
P < .001
a
AVNRT vs no AVNRT, P < .05.
b
Power control vs. no power control, P < .05.
c
Each pathway vs all other pathways.
AVNRT = atrioventricular nodal reentrant tachycardia; PJRT = permanent junctional reciprocating tachycardia.